Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
An insider of DTIL filed a notice of proposed sale under Rule 144 for 8,854 common shares, with an aggregate market value of 35,653.29. The shares are expected to be sold on 01/21/2026 on the NASDAQ through Fidelity Brokerage Services LLC. These shares were acquired on 01/20/2026 through restricted stock vesting from the issuer as compensation, rather than a cash purchase. The filing also reports that Dario J. Scimeca previously sold 665 common shares on 11/03/2025 for gross proceeds of 4,315.19. By signing the notice, the seller represents they are not aware of undisclosed material adverse information about the issuer’s operations.
DTIL received a Rule 144 notice for a planned sale of 10,200 shares of its common stock through Fidelity Brokerage Services LLC on 01/21/2026, to be sold on NASDAQ with an aggregate market value of $41,073.36. These shares were acquired from the issuer on 01/20/2026 through restricted stock vesting as compensation on the same date. The filing notes that the seller represents they are not aware of any material adverse, non-public information about the issuer’s current or prospective operations.
A stockholder of DTIL filed a Rule 144 notice to sell 15,213 common shares, with an aggregate market value of $61,259.71. The proposed sale is through Fidelity Brokerage Services on the NASDAQ, with an approximate sale date of 01/21/2026, and the form notes 13,256,751 shares outstanding. The shares to be sold were acquired on 01/20/2026 through restricted stock vesting from the issuer as compensation. The filing also reports that during the past three months, a holder named John A. Kelly sold 1,303 common shares for gross proceeds of $8,455.17.
Precision BioSciences reports preliminary year-end liquidity and key clinical timelines. The company expects to report approximately $137 million in cash, cash equivalents and restricted cash as of December 31, 2025, based on unaudited, still-subject-to-change figures. It believes that existing cash, potential near-term consideration from license partners, continued fiscal discipline and access to its at-the-market facility together should extend its cash runway through 2028.
The company also outlines upcoming milestones for its gene-editing programs. For the ELIMINATE-B trial of PBGENE-HBV, additional biopsy data are expected in the first half of 2026, with completion of dosing in Cohorts 3, 4 and 5, selection of an optimal dose regimen to stop nucleos(t)ide analog therapy, and initiation of Part 2 expansion. Pending investigational new drug clearance, the FUNCTION-DMD Phase 1/2 trial in Duchenne muscular dystrophy is expected to dose its first patient in late-Q1 or early-Q2 2026, with initial data from multiple patients anticipated by year end 2026.
Precision Biosciences Inc. director Geno Germano reported an open-market purchase of the company’s common stock. On 12/16/2025, he bought 3,000 shares of common stock at a weighted average price of $4.72 per share, with individual trade prices ranging from $4.718 to $4.720.
Following this transaction, Germano beneficially owns 23,883 shares of Precision Biosciences common stock in direct ownership.
Precision BioSciences director Stanley R. Frankel reported buying 2,700 shares of the company’s common stock on December 16, 2025 at a price of $4.70 per share. This insider purchase increased his directly held stake to 19,478 shares. The transaction was reported as a routine filing by a single reporting person.
Precision BioSciences director Melinda Brown reported buying 1,381 shares of the company’s common stock on 12/15/2025 at a weighted average price of $4.97 per share. Following this open-market purchase, she beneficially owns 23,346 shares held directly. The shares were acquired in multiple transactions at prices ranging from $4.95 to $5.01, and the reporting person has undertaken to provide full trade-level pricing details upon request.
Precision BioSciences announced an underwritten offering of 10,815,000 shares of common stock with accompanying one-half warrants to purchase up to 5,407,500 shares at a combined price of $6.14. In lieu of common stock for certain investors, the company is also selling pre-funded warrants to purchase up to 1,400,000 shares with accompanying one-half warrants to purchase up to 700,000 shares at a combined price of $6.139995. Each whole warrant is immediately exercisable at $7.25 per share and expires five years from issuance.
The company estimates net proceeds of approximately $70.0 million, excluding any proceeds from warrant exercises. Funds are intended for ongoing and planned research and development, working capital, and general corporate purposes. The securities are offered off an effective Form S-3 shelf, with closing expected on November 12, 2025, subject to customary conditions. Beneficial ownership limits include 4.99% (or 9.99% at holder election) and 19.99% thresholds as outlined.
Precision BioSciences (DTIL) launched an underwritten primary offering of 10,815,000 shares of common stock with accompanying warrants to purchase 5,407,500 shares, plus pre-funded warrants to purchase up to 1,400,000 shares with accompanying warrants. In total, warrants in this financing cover up to 6,107,500 shares. The combined price is $6.14 per common share plus one-half warrant, and $6.139995 per pre-funded warrant plus one-half warrant. Each warrant is immediately exercisable at $7.25 per share and expires five years from issuance.
The pricing table shows a total offering amount of $75,000,093, underwriting discount of $4,500,006, and proceeds before expenses of $70,500,087. The company estimates net proceeds of approximately $70.0 million, intended for ongoing and planned research and development, working capital, and general corporate purposes. The company does not intend to list the warrants or pre-funded warrants. Shares outstanding are expected to be 22,897,665 after the offering, based on 12,082,665 outstanding as of September 30, 2025.